High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Lung transplant recipients have poor outcomes after COVID-19 infection with mortality. Due to the immunosuppression, they have had poor responses to SARS-CoV-2 vaccine and remain at high risk of poor outcomes. This is a Phase I/II clinical trial to evaluate the safety and immune response from a higher dose mRNA-1273 vaccine among lung transplant recipients who have already received three or four doses of the COVID-19 vaccine.
Epistemonikos ID: 3d46d3a4b0d7e79a120f7e4dd86fb91a8ccdd1ce
First added on: Mar 16, 2022